2025 related articles for article (PubMed ID: 8569195)
1. Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells.
Brasoveanu LI; Altomonte M; Fonsatti E; Colizzi F; Coral S; Nicotra MR; Cattarossi I; Cattelan A; Natali PG; Maio M
Lab Invest; 1996 Jan; 74(1):33-42. PubMed ID: 8569195
[TBL] [Abstract][Full Text] [Related]
2. Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis.
Gorter A; Blok VT; Haasnoot WH; Ensink NG; Daha MR; Fleuren GJ
Lab Invest; 1996 Jun; 74(6):1039-49. PubMed ID: 8667608
[TBL] [Abstract][Full Text] [Related]
3. Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas.
Goslings WR; Blom DJ; de Waard-Siebinga I; van Beelen E; Claas FH; Jager MJ; Gorter A
Invest Ophthalmol Vis Sci; 1996 Aug; 37(9):1884-91. PubMed ID: 8759358
[TBL] [Abstract][Full Text] [Related]
4. Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity.
Brasoveanu LI; Fonsatti E; Visintin A; Pavlovic M; Cattarossi I; Colizzi F; Gasparollo A; Coral S; Horejsi V; Altomonte M; Maio M
J Clin Invest; 1997 Sep; 100(5):1248-55. PubMed ID: 9276743
[TBL] [Abstract][Full Text] [Related]
5. Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas.
Mäenpää A; Junnikkala S; Hakulinen J; Timonen T; Meri S
Am J Pathol; 1996 Apr; 148(4):1139-52. PubMed ID: 8644856
[TBL] [Abstract][Full Text] [Related]
6. Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement-mediated lysis.
Brooimans RA; van Wieringen PA; van Es LA; Daha MR
Eur J Immunol; 1992 Dec; 22(12):3135-40. PubMed ID: 1280224
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of protectin (CD59) down-modulates the susceptibility of human melanoma cells to homologous complement.
Coral S; Fonsatti E; Sigalotti L; De Nardo C; Visintin A; Nardi G; Colizzi F; Colombo MP; Romano G; Altomonte M; Maio M
J Cell Physiol; 2000 Dec; 185(3):317-23. PubMed ID: 11056001
[TBL] [Abstract][Full Text] [Related]
8. Cell-surface density of complement restriction factors (CD46, CD55, and CD59): oral squamous cell carcinoma versus other solid tumors.
Ravindranath NM; Shuler C
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Feb; 103(2):231-9. PubMed ID: 17234541
[TBL] [Abstract][Full Text] [Related]
9. Expression of protectin (CD59) in human melanoma and its functional role in cell- and complement-mediated cytotoxicity.
Brasoveanu LI; Altomonte M; Gloghini A; Fonsatti E; Coral S; Gasparollo A; Montagner R; Cattarossi I; Simonelli C; Cattelan A
Int J Cancer; 1995 May; 61(4):548-56. PubMed ID: 7538980
[TBL] [Abstract][Full Text] [Related]
10. Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection.
Montefiori DC; Cornell RJ; Zhou JY; Zhou JT; Hirsch VM; Johnson PR
Virology; 1994 Nov; 205(1):82-92. PubMed ID: 7526538
[TBL] [Abstract][Full Text] [Related]
11. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).
Niehans GA; Cherwitz DL; Staley NA; Knapp DJ; Dalmasso AP
Am J Pathol; 1996 Jul; 149(1):129-42. PubMed ID: 8686736
[TBL] [Abstract][Full Text] [Related]
12. Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells.
De Nardo C; Fonsatti E; Sigalotti L; Calabrò L; Colizzi F; Cortini E; Coral S; Altomonte M; Maio M
J Cell Physiol; 2002 Feb; 190(2):200-6. PubMed ID: 11807824
[TBL] [Abstract][Full Text] [Related]
13. Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis.
Kuraya M; Yefenof E; Klein G; Klein E
Eur J Immunol; 1992 Jul; 22(7):1871-6. PubMed ID: 1378022
[TBL] [Abstract][Full Text] [Related]
14. Targeted neutralization of the complement membrane attack complex inhibitor CD59 on the surface of human melanoma cells.
Junnikkala S; Hakulinen J; Meri S
Eur J Immunol; 1994 Mar; 24(3):611-5. PubMed ID: 7510237
[TBL] [Abstract][Full Text] [Related]
15. Cell-surface expression of complement restriction factors and sialyl Lewis antigens in oral carcinoma: relevance to chemo-immunotherapy.
Ravindranath NM; Nishimoto K; Chu K; Shuler C
Anticancer Res; 2000; 20(1A):21-6. PubMed ID: 10769630
[TBL] [Abstract][Full Text] [Related]
16. Protection of rat endothelial cells from primate complement-mediated lysis by expression of human CD59 and/or decay-accelerating factor.
Charreau B; Cassard A; Tesson L; Le Mauff B; Navenot JM; Blanchard D; Lublin D; Soulillou JP; Anegon I
Transplantation; 1994 Dec; 58(11):1222-9. PubMed ID: 7527603
[TBL] [Abstract][Full Text] [Related]
17. New monoclonal antibodies in CD59: use for the analysis of peripheral blood cells from paroxysmal nocturnal haemoglobinuria (PNH) patients and for the quantitation of CD59 on normal and decay accelerating factor (DAF)-deficient erythrocytes.
Fletcher A; Bryant JA; Gardner B; Judson PA; Spring FA; Parsons SF; Mallinson G; Anstee DJ
Immunology; 1992 Mar; 75(3):507-12. PubMed ID: 1374058
[TBL] [Abstract][Full Text] [Related]
18. Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59.
Clayton A; Harris CL; Court J; Mason MD; Morgan BP
Eur J Immunol; 2003 Feb; 33(2):522-31. PubMed ID: 12645951
[TBL] [Abstract][Full Text] [Related]
19. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells.
Hakulinen J; Meri S
Lab Invest; 1994 Dec; 71(6):820-7. PubMed ID: 7528832
[TBL] [Abstract][Full Text] [Related]
20. Complement regulatory proteins in normal human esophagus and esophageal squamous cell carcinoma.
Shimo K; Mizuno M; Nasu J; Hiraoka S; Makidono C; Okazaki H; Yamamoto K; Okada H; Fujita T; Shiratori Y
J Gastroenterol Hepatol; 2004 Jun; 19(6):643-7. PubMed ID: 15151618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
